A randomized, double blind, comparative study of vitamin D3 versus placebo in patients with Parkinson disease aged between 45 and 85 years old to improve neurological signs and quality of life

Conditions

Parkinson disease

Yoshiharu Yamamoto, Toshihisa Ishikawa, Yasuo Hozumi, M Ikeda, Naoto Kondo et al. (11 authors)

Cancer Research2013-12-15

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.

Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, Toyama T, Chishima T, Saji S, Yamamoto-Ibusuki M, Iwase H.

2013-05-1614 citations

10.1186/1471-2407-13-239

Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease.

Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, Urashima M.

2013-03-13148 citations

10.3945/ajcn.112.051664

Interventions

Vitamin D3 placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Enrollment at Jikei University Aoto hospital 2. Obtained informed consent 3. Age 45 and more and less than 85 years old

Exclusion criteria

Exclusion criteria: 1. Already taking vitamin D supplement or 1,25 vitamin D 2. History of kidney stone 3. Familial or early onset (< 55 years old) type of Parkinson disease 4. Osteoporosis 5. Other difficulties judged by the physician in charge

Design outcomes

Primary

Measure	Time frame
changes of UPDRS, HY stage, MMSE	—

Secondary

Measure	Time frame
changes of PDQ-39 and EQ-5D	—

Countries

Japan

Contacts

Public ContactEmi Suzuki

Jikei University School of Medicine Division of Molecular Epidemiology

urashima@jikei.ac.jp

Outcome results

None listed